Probiotics as Adjuvants in Vaccine Strategy: Is There More Room for Improvement?

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• The gut microbiota significantly influences immune system development and function.
• Probiotic administration can alter microbiota composition and modulate immune responses.
• This study investigates probiotics as potential adjuvants to enhance vaccine efficacy.

Purpose of the Study:

• To explore the role of probiotics as vaccine adjuvants.
• To review existing evidence on probiotic-mediated immune enhancement for vaccinations.
• To assess the potential and limitations of probiotics in improving vaccine-specific immunity.

Main Methods:

• A comprehensive literature review was conducted.
• The review encompassed mechanistic studies, in vitro data, animal models, and human clinical trials.
• Evidence was synthesized to evaluate probiotic efficacy as a vaccine adjuvant.

Main Results:

• Mechanistic and preclinical studies support the biological plausibility of using microbiota to boost immunity.
• Probiotics have demonstrated promising results as adjuvants in animal models and some human vaccine studies (e.g., influenza, rotavirus).
• Clinical data in humans show controversial outcomes, with variability influenced by probiotic strains, administration protocols, and patient populations.

Conclusions:

• The use of probiotics as vaccine adjuvants is a promising strategy with potential applications.
• Heterogeneity in study designs (strains, timing, patient groups) limits definitive conclusions.
• Further research, particularly in vulnerable groups like the elderly and children, is warranted to optimize probiotic adjuvant therapy for vaccination.